ORL@Cu-MOF Boost Cuproptosis and Suppress Fatty Acid Metabolism for Cancer Lymph Node Metastasis Synergistic Therapy
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.This study introduces a novel nanodrug, ORL@Cu-MOF, that induces cuproptosis and suppresses fatty acid metabolism to treat oral squamous cell carcinoma with lymph node metastasis. Combining it with immunotherapy significantly improves treatment outcomes.
Area Of Science
- Biomedical Engineering
- Cancer Research
- Immunology
Background
- Lymph node metastasis (LNM) in oral squamous cell carcinoma (OSCC) is linked to poor prognosis and high mortality.
- Immunotherapy shows promise for OSCC LNM but faces limited response rates.
- Tumor lipid metabolic reprogramming and hindered cuproptosis impede immunotherapy efficacy.
Purpose Of The Study
- To develop a novel nanodrug for inducing cuproptosis and suppressing fatty acid metabolism in OSCC.
- To investigate the therapeutic potential of the nanodrug alone and in combination with immunotherapy for OSCC LNM.
- To explore the synergistic effects on tumor microenvironment (TME) modulation and treatment outcomes.
Main Methods
- Development of a metal-organic framework (MOF) nanodrug loaded with orlistat (ORL@Cu-MOF).
- In vitro and in vivo evaluation of ORL@Cu-MOF's ability to induce cuproptosis and inhibit fatty acid metabolism.
- Assessment of ORL@Cu-MOF combined with anti-PD-1 (αPD-1) immunotherapy in mouse models.
Main Results
- ORL@Cu-MOF effectively induced cuproptosis and suppressed fatty acid metabolism in OSCC cells.
- The nanodrug demonstrated significant antitumor effects and TME remodeling in vivo.
- Combination therapy with αPD-1 markedly enhanced immunotherapy efficacy, converting 'cold tumors' to 'hot tumors'.
Conclusions
- This study presents a novel strategy combining cuproptosis induction and fatty acid metabolism suppression for metastatic cancer treatment.
- ORL@Cu-MOF shows potential as a therapeutic agent for OSCC LNM, improving immunotherapy response.
- The findings offer new insights into managing metastatic OSCC through targeted nanomedicine and immunotherapy.
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Related Concept Videos
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...